Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis



Rating:

Share or cite this content

Citations should be made in the following way:
M. Kreuter (Heidelberg, Germany), H. Kabitz (Konstanz, Germany), L. Hagmeyer (Solingen , Germany), P. Hammerl ( Immenhausen, Germany), A. Esselmann (Warendorf, Germany), C. Wiederhold (Fulda, Germany), D. Skowasch (Bonn, Germany), C. Stolpe (Ibbenbüren, Germany), M. Joest (Bonn, Germany), S. Veitshans (Böblingen, Germany), M. Höffgen (Rheine, Germany), P. Maqhuzu (Neuherberg, Germany), L. Schwarzkopf (Munich , Germany), A. Hellmann (Rheine , Germany), M. Pfeifer (Donaustauf, Germany), J. Behr (Munich , Germany), R. Karpavicius (Essen , Germany), A. Günther (Gießen , Germany), F. Herth (Heidelberg , Germany), P. Markart (Fulda, Germany). Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry. 1206

Member's Comments

No comment yet.

Related content which might interest you: A cohort of patients with a progressive fibrosing phenotype of interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF): the PROGRESS study Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting Source: International Congress 2014 – ILDs 6 Year: 2014 PROOF-registry: A prospective observational registry to describe the disease course and outcomes of IPF patients in a real-world clinical setting- An interim report Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Diaphragm ultrasound in patients with interstitial lung disease (ILD): a prospective study. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study) Source: Eur Respir J, 57 (2) 2002718; 10.1183/13993003.02718-2020 Year: 2021 A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Assessment of fibrosis in lung biopsies from the European childhood interstitial lung disease (chILD) registry Source: Virtual Congress 2020 – Possible scenarios in the challenging future of rare diffuse parenchymal lung diseases Year: 2020 Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment I Year: 2016 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Prognostic significance of pathologically proven chronic fibrosing interstitial lung diseases with a progressive phenotype (PF-ILDs): single center retrospective cohort Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 A large cohort study of clinical outcomes and prognostic predictors in patients with acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2014 – IPF and surroundings Year: 2014 Idiopathic pulmonary fibrosis (IPF) patients in Poland – preliminary cohort analysis of EMPIRE registry Source: International Congress 2017 – ILDs: clinical aspects Year: 2017 Interstitial lung disease in a single center inception cohort of early rheumatoid arthritis patients Source: International Congress 2015 – Connective tissue disorders Year: 2015 Estimating long-term survival in progressive fibrosing interstitial lung disease (PF-ILD) other than IPF using matched IPF data Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Symptoms and quality of life in relation to lung function and comorbidities in patients with idiopathic pulmonary fibrosis: INSIGHTS-IPF registry Source: International Congress 2016 – IPF clinical Year: 2016 Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013